See more : SAMICK MUSICAL INSTRUMENT Co., Ltd (002450.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Acceleron Pharma Inc. (XLRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acceleron Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Adhi Karya (Persero) Tbk (ADHI.JK) Income Statement Analysis – Financial Results
- The Weir Group PLC (WEGRY) Income Statement Analysis – Financial Results
- Hot Chili Limited (HCH.V) Income Statement Analysis – Financial Results
- Silicon Motion Technology Corporation (SIMO) Income Statement Analysis – Financial Results
- Primary Bank (PRMY) Income Statement Analysis – Financial Results
Acceleron Pharma Inc. (XLRN)
About Acceleron Pharma Inc.
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 92.52M | 73.99M | 13.99M | 13.48M | 27.77M | 18.10M | 14.63M | 57.23M | 15.25M | 80.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 173.92M | 153.95M | 103.90M | 89.73M | 68.58M | 58.40M | 50.90M | 36.05M | 35.32M | 32.71M |
| General & Administrative | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 34.50M | 33.74M | 25.30M | 20.57M | 14.20M | 14.23M | 8.82M | 8.14M |
| Other Expenses | 85.91M | 56.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 40.86M |
| Cost & Expenses | 259.83M | 210.44M | 138.41M | 123.46M | 93.88M | 78.98M | 65.10M | 50.28M | 44.14M | 42.36M |
| Interest Income | 2.87M | 10.71M | 5.57M | 2.55M | 1.85M | 512.00K | 83.00K | 39.00K | 91.00K | 17.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 922.00K | 2.09M | 1.53M | 1.82M |
| Depreciation & Amortization | 3.85M | 3.94M | 3.75M | 2.83M | 1.68M | 1.18M | 1.12M | 915.00K | 1.29M | 3.13M |
| EBITDA | -162.16M | -120.98M | -115.15M | -105.60M | -55.31M | -62.72M | -49.22M | -18.89M | -29.76M | 41.22M |
| EBITDA Ratio | -175.27% | -163.50% | -823.04% | -783.30% | -199.18% | -346.57% | -336.38% | -33.01% | -195.10% | 50.95% |
| Operating Income | -167.31M | -136.45M | -124.41M | -109.98M | -66.11M | -60.88M | -50.46M | 6.95M | -28.89M | 38.56M |
| Operating Income Ratio | -180.83% | -184.40% | -889.24% | -815.84% | -238.04% | -336.40% | -344.89% | 12.15% | -189.39% | 47.65% |
| Total Other Income/Expenses | 1.30M | 11.53M | 5.52M | 1.56M | 9.12M | -3.02M | -795.00K | -28.85M | -3.69M | -2.29M |
| Income Before Tax | -166.01M | -124.92M | -118.90M | -108.42M | -56.99M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Income Before Tax Ratio | -179.42% | -168.83% | -849.82% | -804.26% | -205.21% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| Income Tax Expense | 21.00K | -62.00K | -27.00K | 32.00K | 24.00K | -3.02M | 127.00K | -26.76M | -2.16M | -468.00K |
| Net Income | -166.03M | -124.86M | -118.87M | -108.45M | -57.01M | -63.89M | -51.26M | -21.90M | -32.58M | 36.27M |
| Net Income Ratio | -179.45% | -168.74% | -849.62% | -804.50% | -205.30% | -353.06% | -350.32% | -38.26% | -213.60% | 44.82% |
| EPS | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.73 |
| EPS Diluted | -2.92 | -2.38 | -2.59 | -2.68 | -1.52 | -1.92 | -1.63 | -1.04 | -1.55 | 1.58 |
| Weighted Avg Shares Out | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 20.95M |
| Weighted Avg Shares Out (Dil) | 56.80M | 52.45M | 45.90M | 40.42M | 37.43M | 33.30M | 31.52M | 21.06M | 21.06M | 22.97M |
Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented a set of preliminary interim data from the ongoing SPECTRA Phase...
Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today presented new cardiac and pulmonary function data from the ongoing PULSAR Phase...
Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the ongoing PULSAR and SPECTRA Phase 2 clinical trials...
Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that updates from the ongoing PULSAR and SPECTRA Phase 2 clinical trials...
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript
Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript
Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of -20.00% and -17.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Acceleron Reports Third Quarter 2020 Operating and Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended...
Acceleron Announces Third Quarter 2020 REBLOZYL® Net Sales
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL® (luspatercept-aamt) as reported by its global collaborator, Bristol...
Acceleron Announces REBLOZYL® (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that data from six clinical abstracts on REBLOZYL (luspatercept-aamt) will be...
Source: https://incomestatements.info
Category: Stock Reports